Cancer - Prostate(구연) (NP-042) 전이성 거세저항성 전립선암에서 항암치료 이전의 Enzalutamide의 사용 : 단일기관 경험 울산대학교 서울아산병원 김휘우, 이동현, 유달산, 정인갑, 홍준혁, 김청수, 안한종 Purpose:Enzalutamide can be used as first-line therapy for metastatic castration-resistant prostate cancer(mCRPC) competing with docetaxel chemotherapy. This study aimed to report clinical efficacy of enzalutamide before chemotherapy in mCRPC in our institution. Methods:Single-center, retrospective study including patients that treated with enzalutamide for first-line treatment in mCRPC. Treatment consisted of 160mg enzalutamide and 5mg prednisolone twice daily. Prostate-specific antigen (PSA) response, progression-free survival, overall survival were the outcomes of interest. Result:A total of 133 patients with mCRPC between 2011 and 2019 were included. Median follow-up was 11.5 months. 106(79.7%) patients experienced PSA decline over 50 percent. Time to biochemical and radiological progression was 6.7 and 6.8 months, respectively. Overall survival was 15.7 months. Logistic regression showed androgen deprivation therapy (ADT) less than 1 year is an independent risk factor for PSA unresponsiveness (HR 4.8, p=0.003). Cox proportional model for progression revealed ADT less than 1 year had significant risk for progression after enzalutamide (HR 3.998, p<0.001). Conclusion:Our experience with enzalutamide in mCRPC patients before taxane chemotherapy demonstrates favorable outcomes. Patients with ADT less than 1 year may be unfavorable for enzalutamide before chemotherapy. keywords : prostate cancer, enzalutamide, chemotherapy